Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04833920
Status:
UNKNOWN
Last Update Posted:
2021-04-06
First Post:
2021-04-02
Brief Title:
Effect tDCS of Motor Cortex on Chemotherapy Induced Peripheral Neuropathy
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Effect of Motor Cortex Stimulation by Concentric Electrode Transcranial Direct Current Stimulation on Chemotherapy Induced Peripheral Neuropathy
Status:
UNKNOWN
Status Verified Date:
2021-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chemotherapy induced peripheral neuropathy CIPN occurs in conjunction with the use of anticancer medication such as vinca alkaloids including vincristine taxanes including paclitaxel and platinum preparations including cisplatin and oxaliplatin
Detailed Description:
Chemotherapy induced peripheral neuropathy CIPN occurs in conjunction with the use of anticancer medication such as vinca alkaloids including vincristine taxanes including paclitaxel and platinum preparations including cisplatin and oxaliplatin CIPN is one of several long term side effects of anticancer medications that can appear during and after treatment CIPN symptoms include pain dysesthesia motor and sensory disorders CIPN can also be insufficiently responsive to pharmaceutical therapy similar to other types of refractory neuropathic pain This study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation CE-tDCS over the primary motor cortex M in management of chemotherapy induced peripheral neuropathy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None